WESTON (dpa-AFX) - Biogen Idec Inc. (BIIB) said it received conditional approval from the European Commission for FAMPYRA to improve walking in adult patients with multiple sclerosis or MS who have walking disability. FAMPYRA is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS.1 FAMPYRA can be used alone or in combination with disease modifying therapies, including immunomodulatory drugs.
'With its approval by the European Commission, FAMPYRA has the potential to make a real difference for thousands of people across Europe with both relapsing remitting and progressive forms of MS,' explained Prof. Bernd Kieseier, Department of Neurology, University Hospital Duesseldorf.
Moreover, Ron Cohen, M.D., Acorda's President and CEO stated, 'Studies have shown that even small degrees of walking impairment can have a major negative impact on the patient. The European approval of FAMPYRA allows people with MS in the European Union to have access to a novel therapy that has been shown to improve walking ability across a wide range of impairment, from mild to severe.'
FAMPYRA would be available in Europe, on a country-by-country basis, beginning with Germany in September 2011, with other countries following.
Copyright RTT News/dpa-AFX
© 2011 AFX News
